Pramlintide + Insulin

Montefiore Medical Center · FDA-approved active Small molecule

Pramlintide + Insulin is a Amylin analog + Insulin combination Small molecule drug developed by Montefiore Medical Center. It is currently FDA-approved for Type 1 diabetes mellitus (in combination with insulin), Type 2 diabetes mellitus (in combination with insulin). Also known as: Pramlintide Acetate.

Pramlintide slows gastric emptying and suppresses glucagon secretion, while insulin lowers blood glucose, together improving postprandial glucose control in diabetes.

Pramlintide slows gastric emptying and suppresses glucagon secretion, while insulin lowers blood glucose, together improving postprandial glucose control in diabetes. Used for Type 1 diabetes mellitus (in combination with insulin), Type 2 diabetes mellitus (in combination with insulin).

At a glance

Generic name	Pramlintide + Insulin
Also known as	Pramlintide Acetate
Sponsor	Montefiore Medical Center
Drug class	Amylin analog + Insulin combination
Target	Amylin receptor (pramlintide component); Insulin receptor (insulin component)
Modality	Small molecule
Therapeutic area	Diabetes
Phase	FDA-approved

Mechanism of action

Pramlintide is an amylin analog that acts as a neuroendocrine regulator to delay gastric emptying, suppress postprandial glucagon secretion, and promote satiety. When combined with insulin, it provides complementary glucose-lowering effects: insulin drives glucose uptake and storage, while pramlintide reduces the rate of nutrient absorption and hepatic glucose production after meals. This combination addresses multiple pathophysiologic defects in diabetes.

Approved indications

• Type 1 diabetes mellitus (in combination with insulin)
• Type 2 diabetes mellitus (in combination with insulin)

Common side effects

• Hypoglycemia
• Nausea
• Vomiting
• Anorexia
• Injection site reactions

Key clinical trials

• Two Way Crossover Closed Loop Study Insulin vs Insulin and Pramlintide (NA)
• A Fully Automated Lyumjev and Pramlintide Delivery System for Adults With Type 1 Diabetes (PHASE2, PHASE3)
• Phase 2, Randomized, Open-Label, Crossover, PD/PK Study of a Novel Pram-Insulin Co-Formulation in Adults With T1D (PHASE2)
• A Fully-closed Loop, Pramlintide and Insulin, Artificial Pancreas Clinical Trial for Adults With Type 1 Diabetes (NA)
• Co-administration of Pramlintide and Insulin Via an Automated Dual-hormone Artificial Pancreas System in Adults With Type 1 Diabetes (NA)
• Alleviating Carbohydrate Counting for Patients With Type 1 Diabetes Using a Novel Insulin-plus-pramlintide Artificial Pancreas (NA)
• Glucagon Counterregulation in Type 1 Diabetes (NA)
• Safety and Efficacy of BC LisPram (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Pramlintide + Insulin CI brief — competitive landscape report
• Pramlintide + Insulin updates RSS · CI watch RSS
• Montefiore Medical Center portfolio CI

Frequently asked questions about Pramlintide + Insulin

What is Pramlintide + Insulin?

Pramlintide + Insulin is a Amylin analog + Insulin combination drug developed by Montefiore Medical Center, indicated for Type 1 diabetes mellitus (in combination with insulin), Type 2 diabetes mellitus (in combination with insulin).

How does Pramlintide + Insulin work?

Pramlintide slows gastric emptying and suppresses glucagon secretion, while insulin lowers blood glucose, together improving postprandial glucose control in diabetes.

What is Pramlintide + Insulin used for?

Pramlintide + Insulin is indicated for Type 1 diabetes mellitus (in combination with insulin), Type 2 diabetes mellitus (in combination with insulin).

Who makes Pramlintide + Insulin?

Pramlintide + Insulin is developed and marketed by Montefiore Medical Center (see full Montefiore Medical Center pipeline at /company/montefiore-medical-center).

Is Pramlintide + Insulin also known as anything else?

Pramlintide + Insulin is also known as Pramlintide Acetate.

What drug class is Pramlintide + Insulin in?

Pramlintide + Insulin belongs to the Amylin analog + Insulin combination class. See all Amylin analog + Insulin combination drugs at /class/amylin-analog-insulin-combination.

What development phase is Pramlintide + Insulin in?

Pramlintide + Insulin is FDA-approved (marketed).

What are the side effects of Pramlintide + Insulin?

Common side effects of Pramlintide + Insulin include Hypoglycemia, Nausea, Vomiting, Anorexia, Injection site reactions.

What does Pramlintide + Insulin target?

Pramlintide + Insulin targets Amylin receptor (pramlintide component); Insulin receptor (insulin component) and is a Amylin analog + Insulin combination.

Related

• Drug class: All Amylin analog + Insulin combination drugs
• Target: All drugs targeting Amylin receptor (pramlintide component); Insulin receptor (insulin component)
• Manufacturer: Montefiore Medical Center — full pipeline
• Therapeutic area: All drugs in Diabetes
• Indication: Drugs for Type 1 diabetes mellitus (in combination with insulin)
• Indication: Drugs for Type 2 diabetes mellitus (in combination with insulin)
• Also known as: Pramlintide Acetate